US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Prevail Therapeutics

23.00

0.0000

Volume:- -

Turnover:- -

Market Cap:158.09M

PE:-9.96

High:23.00

Open:23.00

Low:23.00

Close:23.00

52wk High:23.35

52wk Low:9.02

Shares:6.87M

Float Shares:2.02M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3102

EPS(LYR):-2.2175

ROE:-52.34%

ROA:-29.11%

PB:1.40

PE(LYR):-10.37

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Prevail Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.prevailtherapeutics.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PRVL/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PRVL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PRVL\",,,,,undefined,":{"symbol":"PRVL","market":"US","secType":"STK","nameCN":"Prevail Therapeutics","latestPrice":23,"timestamp":1611262800000,"preClose":23,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":2024501,"shares":6873344,"eps":-2.310192,"marketStatus":"Halted","change":0,"latestTime":"01-21 16:00:00 EST","open":23,"high":23,"low":23,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.310192,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"listingDate":1561003200000,"exchange":"NASDAQ","adjPreClose":23,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PRVL\",,,,,undefined,":{"symbol":"PRVL","floatShares":2024501,"roa":"-29.11%","roe":"-52.34%","lyrEps":-2.217515,"shares":6873344,"dividePrice":0,"high":23,"amplitude":0,"preClose":23,"low":23,"week52Low":9.02,"pbRate":"1.40","week52High":23.35,"institutionHeld":0,"latestPrice":23,"eps":-2.310192,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.310192,"open":23,"prevYearClose":23.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PRVL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-01-25","symbol":"PRVL","reason":null,"defaultRemindTime":1611585000000,"announcedDate":"2021-01-14","type":"delisting","dateTimestamp":1611550800000},{"market":"US","date":"2020-11-13","symbol":"PRVL","fiscalQuarterEnding":"2020/09","expectedEps":-0.64,"name":null,"time":"","type":"earning","dateTimestamp":1605243600000,"reportTimeType":"","actualEps":-0.55},{"date":"2020-08-11","symbol":"PRVL","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2020/06","expectedEps":-0.59,"defaultRemindTime":1597132800000,"name":null,"time":"Pre-Market","dateTimestamp":1597118400000,"actualEps":null},{"market":"US","date":"2020-05-14","symbol":"PRVL","fiscalQuarterEnding":"2020/03","expectedEps":-0.51,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1589428800000,"reportTimeType":"pre","actualEps":-0.56},{"market":"US","date":"2020-03-26","symbol":"PRVL","fiscalQuarterEnding":"2019/12","expectedEps":-0.64,"name":null,"time":"","type":"earning","dateTimestamp":1585195200000,"reportTimeType":"","actualEps":-0.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PRVL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PRVL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PRVL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PRVL","date":"2021-01-22","current":-9.955882,"percent":0.521411,"low":-177.180696,"twenty":-127.865727,"median":-10.253791,"eighty":-5.510555,"high":-4.050302,"avg":-63.91702,"sd":61.834439,"marketCap":787704759},"quantilePoints":[],"updateTime":1770693434493},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.prevailtherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.","exchange":"NASDAQ","name":"Prevail Therapeutics","nameEN":"Prevail Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PRVL\",market:\"US\",,,undefined,":null}}